Physician profile
Ashraf Malek
NPI 1427194075
$119,309.59
in general payments reported to CMS, 2019-2025
26 companies · $92K in 2025
The $92K reported for 2025 was more than what 93% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,649 · 2020: $4,668 · 2021: $255 · 2022: $474 · 2023: $3,125 · 2024: $9,280 · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Honoraria: $6,238 · Travel and Lodging: $5,510 · Food and Beverage: $4,370 · Consulting Fee: $3,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,579.00 |
| Honoraria | $6,237.50 |
| Travel and Lodging | $5,509.63 |
| Food and Beverage | $4,369.65 |
| Consulting Fee | $3,567.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $39,610.98 | 2023-2025 | Terlivaz |
| Novo Nordisk INC | $26,478.19 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $24,445.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $9,404.97 | 2023-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $7,036.68 | 2019-2025 | Livdelzi |
| Eisai INC. | $6,647.83 | 2019-2020 | |
| Glaxosmithkline, LLC. | $2,600.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,108.31 | 2019-2025 | Xifaxan |
| Intra-Sana Laboratories | $573.75 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Abbvie INC. | $437.26 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $213.81 | 2019-2024 | Ocaliva |
| Echosens North America, INC. | $200.50 | 2019 | |
| Haemonetics Corporation | $120.20 | 2021-2022 | |
| Shionogi INC | $95.51 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $88.39 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $33.89 | 2024 | Cuvrior |
| Bayer Healthcare Pharmaceuticals INC. | $33.83 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $28.91 | 2020 | |
| Dynavax Technologies Corporation | $24.98 | 2023-2024 | Heplisav-B |
| Grifols USA, LLC | $23.42 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.32 | 2025 | Livtencity |
| Mirum Pharmaceuticals, INC. | $20.27 | 2025 | Cholbam, Chenodal, Livmarli |
| Sobi, INC | $17.23 | 2023 | |
| W. L. Gore & Associates, INC. | $16.00 | 2023 | Gore Cardioform Septal Occluder |
| Dova Pharmaceuticals | $13.43 | 2019 | |
| Shire North American Group INC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.